Browsing by Author "Kang, Byungkon"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Author Correction: Predicting Alzheimer’s disease progression using multi-modal deep learning approach
    (Springer Nature, 2023-08-01) Lee, Garam; Nho, Kwangsik; Kang, Byungkon; Sohn, Kyung‑Ah; Kim, Dokyoon; Alzheimer’s Disease Neuroimaging Initiative; Radiology and Imaging Sciences, School of Medicine
    Correction to: Scientific Reports 10.1038/s41598-018-37769-z, published online 13 February 2019 This Article contains errors. A Supplementary Information file was omitted from the original version of this Article. The Supplementary Information file is now linked to this correction notice.
  • Thumbnail Image
    Item
    MildInt: Deep Learning-Based Multimodal Longitudinal Data Integration Framework
    (Frontiers, 2019-06-28) Lee, Garam; Kang, Byungkon; Nho, Kwangsik; Sohn, Kyung-Ah; Kim, Dokyoon; Radiology & Imaging Sciences, IU School of Medicine
    As large amounts of heterogeneous biomedical data become available, numerous methods for integrating such datasets have been developed to extract complementary knowledge from multiple domains of sources. Recently, a deep learning approach has shown promising results in a variety of research areas. However, applying the deep learning approach requires expertise for constructing a deep architecture that can take multimodal longitudinal data. Thus, in this paper, a deep learning-based python package for data integration is developed. The python package deep learning-based multimodal longitudinal data integration framework (MildInt) provides the preconstructed deep learning architecture for a classification task. MildInt contains two learning phases: learning feature representation from each modality of data and training a classifier for the final decision. Adopting deep architecture in the first phase leads to learning more task-relevant feature representation than a linear model. In the second phase, linear regression classifier is used for detecting and investigating biomarkers from multimodal data. Thus, by combining the linear model and the deep learning model, higher accuracy and better interpretability can be achieved. We validated the performance of our package using simulation data and real data. For the real data, as a pilot study, we used clinical and multimodal neuroimaging datasets in Alzheimer's disease to predict the disease progression. MildInt is capable of integrating multiple forms of numerical data including time series and non-time series data for extracting complementary features from the multimodal dataset.
  • Thumbnail Image
    Item
    Predicting Alzheimer's disease progression using multi-modal deep learning approach
    (Springer Nature, 2019-02-13) Lee, Garam; Nho, Kwangsik; Kang, Byungkon; Sohn, Kyung-Ah; Kim, Dokyoon; Radiology and Imaging Sciences, School of Medicine
    Alzheimer's disease (AD) is a progressive neurodegenerative condition marked by a decline in cognitive functions with no validated disease modifying treatment. It is critical for timely treatment to detect AD in its earlier stage before clinical manifestation. Mild cognitive impairment (MCI) is an intermediate stage between cognitively normal older adults and AD. To predict conversion from MCI to probable AD, we applied a deep learning approach, multimodal recurrent neural network. We developed an integrative framework that combines not only cross-sectional neuroimaging biomarkers at baseline but also longitudinal cerebrospinal fluid (CSF) and cognitive performance biomarkers obtained from the Alzheimer's Disease Neuroimaging Initiative cohort (ADNI). The proposed framework integrated longitudinal multi-domain data. Our results showed that 1) our prediction model for MCI conversion to AD yielded up to 75% accuracy (area under the curve (AUC) = 0.83) when using only single modality of data separately; and 2) our prediction model achieved the best performance with 81% accuracy (AUC = 0.86) when incorporating longitudinal multi-domain data. A multi-modal deep learning approach has potential to identify persons at risk of developing AD who might benefit most from a clinical trial or as a stratification approach within clinical trials.